RecruitingPhase 2NCT05997056

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

Studying Neuroendocrine tumor of pancreas

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Aadi Bioscience, Inc.
Principal Investigator
Willis Navarro, MD
Aadi Bioscience
Intervention
nab-sirolimus(drug)
Enrollment
21 enrolled
Eligibility
18 years · All sexes
Timeline
2023 – 2025

Study locations (4)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05997056 on ClinicalTrials.gov

Other trials for Neuroendocrine tumor of pancreas

Additional recruiting or active studies for the same condition.

See all trials for Neuroendocrine tumor of pancreas →

← Back to all trials